埃克替尼致1例肺癌患者纯红细胞再生障碍性贫血的分析与药学监护  

Analysis and Pharmaceutical Care of Pure Red Cell Aplastic Anemia Caused by Icotinib in a Patient with Lung Cancer

作　　者：王宁[1] 张秀云[1] 党和勤 张金霞 苏凤云 Wang Ning;Zhang Xiuyun;Dang Heqin;Zhang Jinxia;Su Fengyun(Pharmacy Department,Gaotang County People’s Hospital,Shandong Liaocheng 252800,China;Department of Pharmacy,Second Affiliated Hospital of Shandong First Medical University)

机构地区：[1]高唐县人民医院药剂科,山东聊城252800 [2]山东第一医科大学第二附属医院

出　　处：《药物流行病学杂志》2022年第12期828-831,共4页Chinese Journal of Pharmacoepidemiology

基　　金：山东省药品不良反应监测中心项目(编号:2017SDADRKY05)。

摘　　要：埃克替尼为晚期肺癌的一线用药,常见药品不良反应为皮疹、腹泻等,纯红细胞再生障碍性贫血(PRCA)为埃克替尼新的、严重的不良反应。临床药师参与1例肺癌患者应用埃克替尼后出现PRCA的治疗过程,详细分析了发生PRCA的可能原因,并对患者开展药学监护,旨在提高临床医生和药师对该类不良反应的警惕。Icotinib is the first⁃line drug for advanced lung cancer.Its common adverse drug reactions are rash and diarrhea,and pure red cell aplastic anemia(PRCA)is a new and serious adverse reaction.Clinical pharmacists participa⁃ted in the treatment of PRCA in a patient with lung cancer who was treated with icotinib.The possible causes of PRCA were analyzed in detail,and the patient was given whole⁃process pharmaceutical care,aiming to improve the vigilance of clini⁃cians and pharmacists on PRCA.

关 键 词：埃克替尼 纯红细胞再生障碍性贫血 肺癌 药品不良反应 药学监护 

分 类 号：R97[医药卫生—药品]